Every 8-K that Ginkgo Bioworks Holdings Inc (DNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNA filings page.
Ginkgo Bioworks Holdings, Inc. reported second quarter 2026 revenue of $20 million, down 48% from $39 million a year earlier, reflecting program rationalization from restructuring. Net loss from continuing operations was $(57) million, versus $(53) million in the prior-year quarter, and Adjusted EBITDA was $(36) million, down from $(25) million. Cash, cash equivalents and marketable securities totaled $302 million as of June 30, 2026, and the company reaffirmed full-year 2026 cash burn guidance of ($150)-($125) million.
Strategically, Ginkgo highlighted growth in autonomous lab infrastructure. It won government-backed contracts to build cloud labs at Caltech, Northwestern, the University of Maryland and a $47 million, 97-instrument autonomous lab for EMSL at Pacific Northwest National Laboratory, while continuing to scale its Nebula facility. Its new ADME-One pharma service, positioned as 10x cheaper than WuXi, signed 17 customers in its first six weeks.
Ginkgo Bioworks Holdings, Inc. plans to host a presentation and Q&A session reviewing its business performance for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, beginning at 4:30 p.m. ET.
The session will be webcast via Ginkgo's investor relations website, with a replay available. Shareholders may submit questions in advance via X to @Ginkgo using hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com. The company highlights its websites, blog, news site, and social media channels as outlets for potentially material information.
Ginkgo Bioworks Holdings, Inc. reported the results of its 2026 annual meeting of shareholders held on June 11, 2026. Shareholders representing 39,536,848 Class A shares and 8,405,525 Class B shares were present, equal to 77.15% of the combined voting power and 93.77% of the Class B voting power.
Holders of Class B stock, who have ten votes per share, re-elected Jason Kelly and Reshma Shetty, each receiving 84,007,040 votes for and 48,210 votes against. Combined Class A and B holders re-elected Ross Fubini, Christian Henry, Sri Kosuri, and Harry E. Sloan with for-vote totals between about 94.2 million and 100.1 million.
Shareholders also approved the ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 119,527,721 votes for and 267,727 against. In an advisory vote, shareholders approved the compensation of the company’s named executive officers, with 95,058,585 votes for and 12,502,153 against.
Ginkgo Bioworks Holdings, Inc. reported first quarter 2026 results and highlighted its post-divestiture focus on autonomous labs. Revenue was $19.5 million, down 49% from the prior year quarter, largely due to program rationalization and the absence of prior non-cash deferred revenue releases.
The company posted a GAAP net loss from continuing operations of $76.1 million, modestly improved from $83.3 million a year earlier, and an Adjusted EBITDA loss of $42.3 million compared with $44.2 million. Cash, cash equivalents and marketable securities totaled $373 million as of March 31, 2026.
Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026, which is now reported as discontinued operations. Management emphasized scaling its Nebula autonomous lab, growth in its Cloud Lab, Datapoints and Solutions offerings, and reaffirmed expected full-year 2026 total cash burn of $(150)–$(125) million.
Ginkgo Bioworks Holdings, Inc. completed the sale of substantially all operations of its Biosecurity segment to Tower Biosecurity, Inc. on April 3, 2026. In return, Ginkgo received common stock representing approximately 20% of Tower Biosecurity’s fully diluted equity, which will be accounted for under the equity method.
Because this deal represents a strategic shift, Biosecurity’s historical results will be reported as discontinued operations. Unaudited pro forma statements show how Ginkgo’s balance sheet and results for 2023–2025 would look without Biosecurity, with lower revenue but slightly reduced net losses over all three years.
Ginkgo Bioworks Holdings, Inc. entered into a Stock Purchase Agreement under which its wholly owned subsidiary will transfer all issued and outstanding equity of Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc. This business represents substantially all of Ginkgo’s Biosecurity segment operations.
In return, Tower Biosecurity will issue shares of its common stock to Ginkgo’s subsidiary, equal to approximately 20% of Tower’s fully diluted equity. The transaction is expected to close in the first half of 2026, subject to customary closing conditions.
Ginkgo Bioworks Holdings, Inc. reported weaker 2025 revenue alongside significantly reduced losses and a major strategic shift. Total revenue for 2025 was $170.2 million, down from $227.0 million (a 25% decline), with Cell Engineering revenue falling to $132.7 million and Biosecurity revenue to $37.4 million. Despite this, the GAAP net loss narrowed sharply to $(312.8) million from $(547.0) million, and Adjusted EBITDA improved to $(167.0) million from $(293.3) million, reflecting lower operating expenses and restructuring benefits.
The company ended 2025 with $423 million in cash, cash equivalents and marketable securities, down from higher prior-year levels, and guided for 2026 total cash burn of $(150)–$(125) million. Ginkgo plans to divest its non‑core biosecurity business to investors in exchange for a minority equity stake, turning it into a standalone private company, while refocusing the business on autonomous labs. Management highlighted expansion of its frontier autonomous lab in Boston, new collaboration results with OpenAI showing a 40% improvement in cell‑free protein synthesis, and a $47 million autonomous lab contract with Pacific Northwest National Laboratory as key proof points for the new strategy.
Ginkgo Bioworks Holdings, Inc. reported a leadership transition in its operating roles. Effective January 1, 2026, co‑founder Dr. Reshma Shetty will transition her Chief Operating Officer responsibilities to Chief Executive Officer Dr. Jason Kelly and executive Jennifer Wipf. Dr. Shetty will remain President, continue serving on the Board of Directors, and focus on expanding and using the company’s autonomous lab to deliver cell engineering service offerings, while Dr. Kelly will take on the principal operating officer policymaking duties.
Jennifer Wipf, previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will oversee operations functions such as day‑to‑day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly. The changes keep Dr. Shetty in a substantial policymaking role while formalizing broader operating responsibilities for Dr. Kelly and Ms. Wipf.
Ginkgo Bioworks (DNA) furnished an 8-K announcing it issued a press release with its financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The filing, dated November 6, 2025, is an administrative disclosure under Item 2.02 (Results of Operations and Financial Condition) and includes the Inline XBRL cover page file as Exhibit 104.
Ginkgo Bioworks Holdings entered into a Sales Agreement with Allen & Company LLC to conduct an at-the-market offering of up to $100,000,000 of its Class A common stock. Under this arrangement, Ginkgo may, at its option, sell shares from time to time through or directly to Allen as sales agent under an effective Form S-3 shelf registration and a prospectus supplement dated September 4, 2025.
The agent will use commercially reasonable efforts to execute sales and will earn a commission of up to 3.0% of the gross proceeds from each share sale. Either party can terminate the agreement with written notice. Ginkgo currently expects any net proceeds, if shares are sold, to be used for general corporate purposes, including funding operations, technology development, working capital, and capital expenditures. The company notes there is no assurance any shares will actually be issued under this at-the-market program and highlights potential dilution and other risks in its risk factor disclosures.
Ginkgo Bioworks Holdings, Inc. has reached a proposed settlement to resolve several stockholder derivative lawsuits filed on the company’s behalf in federal and Delaware courts. The company entered into a Stipulation and Agreement of Settlement on May 27, 2025, and on August 21, 2025, a federal court granted preliminary approval, ordered notice to stockholders, and set a final hearing for December 18, 2025 at 1:30 p.m. PST.
If the settlement receives final court approval, Ginkgo will receive a $4,125,000 payment funded by insurance, from which plaintiffs’ counsel plans to request $2,750,000 in fees and expenses. The company will also adopt and maintain specified corporate governance and other reforms, and the plaintiffs will dismiss the derivative actions with prejudice and provide releases related to the matters alleged.